Clinical Trials Browser

Phase 1/2 × stenoparib × Breast × Clear all

NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Phase 1/2 Completed

BreastGynecologicLymphoidOther hematologic neoplasm

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

NCT02396433 2015-08-25

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Phase 1/2 Withdrawn

Breast Neoplasms